Akari Therapeutics Shares Jump As KRAS Cancer News Returns
Akari Therapeutics shares more than doubled in premarket trading Friday after its lead cancer drug showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement. The stock was quoted at $10.15, up from Thursday’s $5.14 close. Akari plans to start Phase 1 human trials of AKTX-101 by mid-2027. The company reported $2.8 million in cash at March 31.